NextCure (NASDAQ:NXTC – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.39), FiscalAI reports.
NextCure Stock Performance
Shares of NXTC opened at $5.98 on Thursday. NextCure has a fifty-two week low of $1.55 and a fifty-two week high of $15.74. The company has a market capitalization of $27.38 million, a price-to-earnings ratio of -0.88 and a beta of 1.22. The firm has a 50-day simple moving average of $6.04 and a 200-day simple moving average of $7.60.
Analyst Upgrades and Downgrades
NXTC has been the subject of a number of research analyst reports. Wall Street Zen raised NextCure from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings upgraded NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday, August 13th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.00.
View Our Latest Report on NXTC
Insider Transactions at NextCure
In related news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The shares were purchased at an average price of $4.83 per share, for a total transaction of $27,173.58. Following the transaction, the insider directly owned 728,045 shares of the company’s stock, valued at approximately $3,516,457.35. The trade was a 0.78% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders bought 15,537 shares of company stock valued at $77,603. Insiders own 11.90% of the company’s stock.
About NextCure
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.
Featured Stories
- Five stocks we like better than NextCure
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
